. The Company We are a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. As a result of our acquisition of a 12-lipoxygenase (12-LOX) platform of assets in December 2025 (as described in more detail below), we transitioned our primary strategic focus to the development of CAD-1005 for the treatment of immune-mediated and thrombotic disorders. Our lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor be...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001213900-26-036946 | EDGAR | 85K words |
| 2025-03-13 | 2024-12-31 | 0001213900-25-023759 | EDGAR | — |
| 2024-03-11 | 2023-12-31 | 0001213900-24-021133 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001213900-23-024260 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001213900-25-107816 | EDGAR | 20K words |
| 2025-08-11 | 2025-06-30 | 0001213900-25-073885 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001213900-25-040788 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001213900-24-095393 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001213900-24-066107 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001213900-24-041014 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001213900-23-084937 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001213900-23-065223 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001213900-23-037929 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001213900-26-038014 | EDGAR | 11K words |
| 2026-03-31 | 0001213900-26-036937 | EDGAR | — |
| 2026-03-12 | 0001213900-26-026646 | EDGAR | — |
| 2026-02-24 | 0001213900-26-019606 | EDGAR | — |
| 2025-12-23 | 0001213900-25-125433 | EDGAR | — |
| 2025-12-16 | 0001213900-25-121932 | EDGAR | — |
| 2025-12-11 | 0001213900-25-120360 | EDGAR | — |
| 2025-12-01 | 0001213900-25-116307 | EDGAR | — |
| 2025-11-18 | 0001213900-25-112123 | EDGAR | — |
| 2025-11-10 | 0001213900-25-107949 | EDGAR | — |
84 total filings indexed. 61 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001937993 |
| Ticker | CVKD |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.cadrenal.com |
| Listed | 2023-01-20 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report